Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Starpharma Pty Ltd National Institute of Allergy and Infectious Diseases (NIAID) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Microbicide Trials Network |
---|---|
Information provided by: | Starpharma Pty Ltd |
ClinicalTrials.gov Identifier: | NCT00442910 |
There is an urgent need for HIV prevention methods that women can initiate and control themselves. Topical microbicides, substances that kill microbes, represent one such method. The purpose of this study is to assess the safety and to evaluate the acceptability of 3% w/w SPL7013 gel, a topical microbicide, when administered intravaginally for 14 consecutive days in healthy, sexually active HIV uninfected women.
Condition | Intervention | Phase |
---|---|---|
Healthy |
Drug: SPL7013 Gel Drug: Placebo Gel |
Phase I |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety Study |
Official Title: | Phase 1 Study of the Safety and Acceptability of 3% w/w SPL7013 Gel (VivaGel™) Applied Vaginally in Sexually Active Young Women |
Estimated Enrollment: | 40 |
Study Start Date: | July 2007 |
Estimated Study Completion Date: | March 2009 |
Estimated Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
Intravaginal application of 3.5 g SPL7013 gel twice daily for 14 days
|
Drug: SPL7013 Gel
3% vaginal gel
|
2: Placebo Comparator
Intravaginal application of 3.5 g placebo gel twice daily for 14 days
|
Drug: Placebo Gel
Placebo for SPL7013 gel
|
Women continue to comprise a growing proportion of the new HIV infections around the world. A growing body of data suggests that a safe and effective topical microbicide will be a real option of prevention for women in the future. The purpose of this study is to assess the safety and acceptability of 3% SPL7013 Gel when administered intravaginally, twice daily for 14 consecutive days in healthy, sexually-active, HIV-uninfected women.
The expected duration of this study for each participant is 21 days. Study participants will be randomly assigned to one of two arms. Participants in Arm 1 will apply 3.5 g of SPL7013 gel intravaginally twice daily for 14 consecutive days. Participants in Arm 2 will apply a placebo gel intravaginally twice daily for 14 consecutive days. Starpharma produces SPL7013 gel (VivaGel) and will provide it for this study.
After enrollment, participants will attend three study visits. These visits will occur on Days 7, 14, and 21. A follow-up safety visit will occur if necessary. Medical and menstrual history, targeted physical exam, urine and blood collection, cervical swabs, and vaginal smears will occur at all visits. A colposcopy will occur at least once. On Day 2, participants will take part in a phone assessment.
Ages Eligible for Study: | 18 Years to 24 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Florida | |
University of South Florida | Recruiting |
Tampa, Florida, United States, 33606 | |
Contact: Patricia Emmanual, MD pemmanue@health.usf.edu | |
Principal Investigator: Patricia Emmanuel, MD | |
Puerto Rico | |
University of Puerto Rico | Recruiting |
San Juan, Puerto Rico, 00936-5067 | |
Contact: Irma Febo, MD febo.irma@fstrf.org |
Study Chair: | Ian McGowan, MD, PhD | University of California Geffen School of Medicine |
Responsible Party: | DAIDS ( Rona Siskind ) |
Study ID Numbers: | MTN-004; SPL7013-006 |
Study First Received: | March 2, 2007 |
Last Updated: | September 29, 2008 |
ClinicalTrials.gov Identifier: | NCT00442910 |
Health Authority: | United States: Food and Drug Administration |
Safety and Acceptability |
Healthy |